MASLD (metabolic dysfunction–associated steatotic liver disease) is fat build-up in the liver that occurs alongside metabolic risk factors such as excess weight, type 2 diabetes, high blood pressure or abnormal lipids. It ranges from simple fat (steatosis) through inflammation (MASH) to scarring (fibrosis) and, rarely, cirrhosis — and the amount of fat is not the same as the amount of scarring.
Section accent: --clay (MASLD pillar, scoped in-family).
What MASLD actually means
MASLD stands for Metabolic dysfunction–Associated Steatotic Liver Disease. Broken into plain parts:
- Steatotic — the liver is storing fat (steatosis).
- Metabolic dysfunction–associated — that fat sits alongside at least one cardiometabolic risk factor (excess weight or central adiposity, prediabetes or type 2 diabetes, high blood pressure, high triglycerides, or low HDL).
In other words, MASLD is the liver's readout of whole-body metabolic health. It is not a rare or exotic diagnosis — it is now the most common chronic liver condition in the world, affecting roughly a quarter to a third of adults and a majority of people with type 2 diabetes or significant obesity. That prevalence is exactly why the distinctions on this page matter: most fatty livers are low-risk, but a meaningful minority are not, and the label "fatty liver" alone doesn't tell you which one you have. → Who Should Be Evaluated?
The words changed: NAFLD → MASLD, NASH → MASH
If you were told years ago that you had NAFLD or NASH, the disease didn't change — the name did.
In 2023 an international consensus renamed the condition:
- NAFLD → MASLD (Metabolic dysfunction–Associated Steatotic Liver Disease). The old name, "non-alcoholic fatty liver disease," defined the condition by what it wasn't. The new name defines it by what it is: a metabolic disease.
- NASH → MASH (Metabolic dysfunction–Associated Steatohepatitis) — the inflammatory, injurious form.
- A new overlap term, MetALD, describes metabolic fatty liver plus meaningful alcohol intake — recognizing that many people have both drivers rather than one.
The rename removed a stigmatizing "alcoholic" framing and, more importantly, put the metabolic cause in the name. Throughout this site we use the current terms (MASLD/MASH), and treat them as identical in substance to the conditions formerly called NAFLD/NASH.
How fat gets into the liver — insulin resistance and visceral fat
MASLD is not primarily a problem of eating fatty food. It is fundamentally a problem of insulin resistance and where the body stores energy.
- Visceral fat — fat packed around the abdominal organs — is metabolically active and releases fatty acids and inflammatory signals into the portal blood that drains straight to the liver. This is why central adiposity (waist size) tracks with liver fat better than overall weight, and why even a "normal-weight" person with visceral fat can develop lean MASLD.
- Insulin resistance means muscle and fat tissue respond poorly to insulin, so the body compensates with higher insulin levels. High insulin drives the liver to make new fat (de novo lipogenesis) and impairs its ability to export and burn fat.
- Hepatic insulin resistance is the liver's own version of the problem. A liver full of fat handles insulin poorly, so it keeps releasing glucose when it shouldn't — which raises blood sugar and worsens the metabolic picture, feeding the cycle.
The practical takeaway: MASLD, type 2 diabetes and cardiovascular disease share the same soil. Treating the liver in isolation misses the point. → Obesity & Insulin Resistance · MASLD & Cardiovascular Risk
The spectrum — four different things, never conflated
This is the single most important idea on every W8Experts liver page. MASLD is not one thing; it is a spectrum, and the stages are not interchangeable.
- Steatosis (fat). Fat stored in liver cells. Common, and on its own usually low-risk. Most people with steatosis never progress.
- MASH (inflammation and injury). Fat plus inflammation and hepatocyte damage — steatohepatitis. This is the form that actively drives scarring. It cannot be diagnosed by the amount of fat alone.
- Fibrosis (scarring). The liver's scar-tissue response to ongoing injury. Fibrosis stage is the strongest predictor of serious liver outcomes — more than fat, more than enzymes. It is staged F0–F4 (see below).
- Cirrhosis (F4). Advanced, architecture-distorting scarring. It raises the risk of liver failure, portal hypertension and hepatocellular carcinoma (HCC, liver cancer) — and can develop even in people who feel well.
The mismatch that defines this field: fat in the liver ≠ fibrosis in the liver. One person can have a strikingly fatty liver with almost no scarring; another can have only modestly abnormal tests but clinically important fibrosis. That is why "you have a fatty liver" is a starting point, not an answer — and why the whole diagnostic pathway exists to separate finding fat from finding risk. → The W8Experts Diagnostic Approach
Fibrosis stages F0–F4
Fibrosis is described in five stages. Roughly:
| Stage | What it describes |
|---|---|
| F0 | No fibrosis |
| F1 | Mild fibrosis (limited scarring) |
| F2 | Moderate ("significant") fibrosis — scarring extends further |
| F3 | Advanced ("bridging") fibrosis — bands of scar link regions of the liver |
| F4 | Cirrhosis — advanced scarring distorting liver architecture |
The clinically important threshold is around F2 and above ("at-risk" fibrosis), because that is where the risk of progression and complications rises and where medications now carry specific indications. This is not a value judgment about the person — it is a way of matching attention to actual risk. F2–F3 is exactly the range for which the first MASH medications are approved. → MASH Medications
Where cirrhosis and liver cancer fit
Only a minority of people with MASLD progress through MASH and fibrosis to cirrhosis — but MASLD is now a leading and rising cause of cirrhosis, liver transplantation and hepatocellular carcinoma worldwide, simply because the condition is so common. Cirrhosis is largely irreversible, though its complications can still be reduced, and it warrants specialist surveillance (including for HCC). The reassuring corollary: catching and treating disease before this stage — when fat and even fibrosis are more reversible — is precisely what risk stratification is for. → Fatty Liver & Weight Loss
Why "fat" and "fibrosis" get measured differently
Because fat and scarring are different things, they are measured with different tools — a distinction patients (and sometimes reports) blur:
- Liver fat is estimated by ultrasound, CT, MRI, MRI-PDFF (a precise fat-fraction measurement) and CAP on a FibroScan device.
- Liver fibrosis is estimated by the FIB-4 blood score, by liver stiffness on elastography (VCTE/FibroScan or MRE), and — as a reference standard — by biopsy.
A FibroScan visit can report both: a CAP number (fat) and a kPa stiffness number (fibrosis). They answer different questions. Confusing "how much fat" with "how much scar" is the most common misreading in this whole area. → FibroScan & Elastography · FIB-4 Explained
SIGNATURE — "What the evidence says: What MASLD is"
- What we know: MASLD is metabolic fatty liver disease on a spectrum from steatosis → MASH → fibrosis → cirrhosis; fibrosis stage (not fat amount) most predicts outcomes; insulin resistance and visceral fat are central drivers.
- What we think: Naming the metabolic cause (MASLD/MASH) reflects the biology better and should push care toward treating the whole metabolic picture, not just the liver.
- What we don't know: Exactly who among people with simple steatosis will progress, and how much of the risk is genetic versus metabolic in any given person.
- What patients should do: Understand which part of the spectrum you're being told about, get risk-stratified rather than just labeled, and address the underlying metabolic drivers. → Who Should Be Evaluated?
Questions patients ask
Is MASLD the same as fatty liver?
Essentially yes — MASLD is the current medical name for metabolic fatty liver disease. It specifies that the fat is linked to metabolic risk factors. Grade A 🟢
What's the difference between MASLD and MASH?
MASLD is the umbrella term (fat, with or without inflammation). MASH is the subset with inflammation and cell injury that can drive scarring. Most MASLD is not MASH. Grade A 🟢
Why was NAFLD renamed to MASLD?
A 2023 consensus renamed NAFLD→MASLD and NASH→MASH to reduce stigma and name the metabolic cause instead of defining the disease as "non-alcoholic." The condition itself is unchanged. Grade A 🟢
Is fat in the liver the same as scarring?
No — and this is the key point. You can have a very fatty liver with little scarring, or modest fat with important fibrosis. Fibrosis is what most predicts serious outcomes. Grade A 🟢 → Diagnostic Approach
What is hepatic insulin resistance?
It's the liver's own resistance to insulin: a fat-laden liver handles insulin poorly and keeps releasing glucose, raising blood sugar and worsening the metabolic cycle that drives more liver fat. Grade A 🟢
Can thin people have MASLD?
Yes. "Lean MASLD" occurs, usually with visceral fat, insulin resistance or genetic factors — so a normal weight doesn't exclude it. Grade B 🟡
What are the fibrosis stages F0 to F4?
F0 is no scarring, F1 mild, F2 moderate ("significant"), F3 advanced ("bridging"), and F4 is cirrhosis. F2 and above is the "at-risk" range that changes management. Grade A 🟢
Does MASLD always lead to cirrhosis?
No. Only a minority progresses to cirrhosis, usually over years and through MASH and fibrosis first. Fibrosis stage is the key predictor, which is why it's assessed. Grade A 🟢
Can MASLD cause liver cancer?
It can, mainly once fibrosis or cirrhosis develops, and MASLD is a rising cause of liver cancer worldwide because it's so common. Risk is concentrated in advanced disease. Grade A 🟢
Is MASLD reversible?
Often, earlier in the spectrum — liver fat and MASH inflammation respond well to metabolic improvement. Fibrosis improves more slowly; cirrhosis is largely irreversible. Earlier is more reversible. Grade A 🟢 → Fatty Liver & Weight Loss
Is MASLD serious or should I not worry?
Both can be true. Most steatosis is low-risk, but on average people with MASLD are more likely to be harmed by cardiovascular disease than by their liver — so it's a signal worth acting on. Grade A 🟢 → MASLD & Cardiovascular Risk
KEEP READING
- Who Should Be Evaluated? — the risk profile, and what an incidental "fatty liver" on a scan should trigger.
- The W8Experts Diagnostic Approach — how we separate finding fat from finding risk.
- FIB-4 Explained and FibroScan & Elastography — the two assessments people confuse.
- "My Liver Tests Are Normal…" — why normal enzymes don't rule out disease.
- MASLD & Cardiovascular Risk — why the biggest threat is often the heart, not the liver.
Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: 2026-08-10 · References: AASLD Practice Guidance on MASLD (2023) and subsequent semaglutide/MASH labeling update; EASL–EASD–EASO clinical practice guidance; MASLD/MASH nomenclature consensus (2023). Educational; not individualized advice.
